A Study of SGN-CD228A in Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 240
Summary
- Conditions
- Breast Cancer
- Colorectal Cancer
- Cutaneous Melanoma
- Non -Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Pleural Mesothelioma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.
This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.
Tracking Information
- NCT #
- NCT04042480
- Collaborators
- Not Provided
- Investigators
- Study Director: Phillip Garfin, MD, PhD Seagen Inc.
Get Well Soon